Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

Abstract

Background Testing of vaccine candidates to prevent infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an older population is important, since increased incidences of illness and death from coronavirus disease 2019 (Covid-19) have been associated with an older age. Methods We conducted a phase 1, dose-escalation, open-label trial of a messenger RNA vaccine, mRNA-1273, which encodes the stabilized prefusion SARS-CoV-2 spike protein (S-2P) in healthy adults. The trial was expanded to include 40 older adults, who were stratified according to age (56 to 70 years or ≥71 years). All the participants were assigned sequentially to receive two doses of either 25 μg or 100 μg of vaccine administered 28 days apart. Results Solicited adverse events were predominantly mild or moderate in severity and most frequently included fatigue, chills, headache, myalgia, and pain at the injection site. Such adverse events were dose-dependent and were more common after the second immunization. Binding-antibody responses increased rapidly after the first immunization. By day 57, among the participants who received the 25-μg dose, the anti–S-2P geometric mean titer (GMT) was 323,945 among those between the ages of 56 and 70 years and 1,128,391 among those who were 71 years of age or older; among the participants who received the 100-μg dose, the GMT in the two age subgroups was 1,183,066 and 3,638,522, respectively. After the second immunization, serum neutralizing activity was detected in all the participants by multiple methods. Binding- and neutralizing-antibody responses appeared to be similar to those previously reported among vaccine recipients between the ages of 18 and 55 years and were above the median of a panel of controls who had donated convalescent serum. The vaccine elicited a strong CD4 cytokine response involving type 1 helper T cells. Conclusions In this small study involving older adults, adverse events associated with the mRNA-1273 vaccine were mainly mild or moderate. The 100-μg dose induced higher binding- and neutralizing-antibody titers than the 25-μg dose, which supports the use of the 100-μg dose in a phase 3 vaccine trial. (Funded by the National Institute of Allergy and Infectious Diseases and others; mRNA-1273 Study ClinicalTrials.gov number, NCT04283461 .)

Phase 1 Assessment of the Safety and Immunogenicity of an mRNA- Lipid Nanoparticle Vaccine Candidate Against SARS-CoV-2 in Human Volunteers

“…Observed local reactions were almost exclusively cases of transient mild to moderate injection site pain; of the 415 total administered doses of CVnCoV at any dosage only three resulted in transient severe local pain, all after the first dose (one each in the 2, 4 and 8 µg groups). The frequency and severity of solicited systemic AEs increased with dosage level and were generally more frequent and of higher intensity after the second dose than the first, as has been observed with other mRNA SARS-CoV-2 vaccine candidates[20][21][22]. These systemic AEsmainly consisted of transient mild or moderate headache and fatigue, and to a lesser extent myalgia and chills.…”

Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?

“…+ T cell response was induced by mRNA-1273 vaccination. In another small study involving old adults (>56 years old), mRNA-1273 at 25 and 100 μg also demonstrated good safety and efficacy profiles (Anderson et al, 2020). Importantly, mRNA-1273 was recently tested in a large phase III COVE trial with >30,000 participants (NCT04470427) and demonstrated a 94.5% rate of protection against COVID-19 (https://investors.…”

COVID-19 basics and vaccine development with a Canadian perspective

“…An LNP-mRNA vaccine mRNA-1273 developed by Moderna/NIAID also induced immune responses with no safety issues in a phase 1 clinical trial (Jackson et al 2020). Another phase 1 trial with adults at the age of 56 and older showed anti-SARS-CoV-2 immune responses after 2 nd immunization in all vaccinees with mild to moderate adverse reactions to the vaccine (Anderson et al 2020). InterVac.…”